Lund, Sweden, 12 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq in New York, from 17:00-17:30 EDT, on Tuesday 19 May, 2026. Read more…
13 May 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it will present data on POLB 001 at the European Hematology Association Congress (“EHA”), taking place 11-14 June 2026 in Stockholm, Sweden. Read more…
TX001 is an engineered Regenerative Macrophage Therapy for end-stage liver disease (ESLD) with anti-inflammatory and anti-fibrotic properties These new preclinical data demonstrate RTX001’s pharmacology, safety, tolerability, and efficacy in mouse models, with reduced fibrosis and inflammation observed Results confirm RTX001’s positive preclinical safety and therapeutic profile ahead of interim results from Resolution’s Phase I/II EMERALD […]
Brings more than 20 years of neurology, clinical development, and translational experience as AstronauTx prepares to advance its lead programmes into clinical development AstronauTx also appoints Deb Gouveia as Vice President, Clinical Operations and Development Strategy to further strengthen clinical development capabilities London, UK, 12 May 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics […]
New system combines Kaleido with Diabeloop’s DBLG2 algorithm and Dexcom G7, with first commercial deliveries in Germany and the Netherlands planned for later this summer Enables insulin automation to be controlled directly from the user’s smartphone, rather than a separate dedicated handset Starting on Kaleido today with Diabeloop’s DBLG1 algorithm is the fastest path to […]
